Evidence map›Paper›PMID 40583299›Full record

ReviewFuture oncology (London, England)2026

Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review.

Paul E Dato, Jose De La Cerda, Andrew J Armstrong, Arun A Azad, Ciara Conduit, Gabriel P Haas, Kenneth Kernen, Zachary W Klaassen, Raj Patel, Fred Saad and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Paul E DatoGenesis Healthcare Partners, San Diego, CA, USA.
Jose De La CerdaUrology San Antonio, San Antonio, TX, USA.
Andrew J ArmstrongDivisions of Medical Oncology and Urology, Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, USA.
Arun A AzadMedical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Ciara ConduitMedical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Gabriel P HaasGlobal Medical Affairs, Astellas Pharma Inc, Northbrook, IL, USA.
Kenneth KernenMichigan Institute of Urology, Troy, MI, USA.
Zachary W KlaassenDivision of Urology, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Raj PatelFormerly of Pfizer Inc., New York, NY, USA.
Fred SaadCentre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, QC, Canada.
Neal D ShoreCarolina Urologic Research Center, Myrtle Beach, SC, USA.ORCID 0000-0001-5767-0548
Stephen J FreedlandDepartment of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Cancer Center, Los Angeles, CA, USA.
Lawrence I KarshAdventHealth Urology, Denver, CO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

goalTo present data from published clinical trials of treatment of patients with prostate cancer with enzalutamide described in plain language and in a dashboard format available at: https://clinical-trials.dimensions.ai/enzalutamide-clinical-review/. RATIONALE: Treatments that are clinically active in advanced prostate cancer may benefit patients as they are treated earlier in the disease.

objectiveTo show how overall survival improves as patients are treated with enzalutamide earlier in the disease.

Indexed as

Antineoplastic AgentsPhenylthiohydantoinProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantBenzamidesClinical Trials as TopicHumansMaleNeoplasm StagingNitrilesTreatment OutcomeAntineoplastic AgentsBenzamidesenzalutamideNitrilesPhenylthiohydantoinadvanced prostate cancerenzalutamidemetastasis-free survivaloverall survivalpatient-reported outcomesPlain language reviewprostate cancerprostate neoplasms

Identifiers

PMID40583299
PMCPMC12915792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.